Recombinant lispro insulin75/25(Gan & Lee Pharma)

双时相重组赖脯胰岛素注射液75/25(甘李药业)

Report date: 2025/06/26 14:13:29

Base Information

Drug NameRecombinant lispro insulin75/25(Gan & Lee Pharma)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGan & Lee Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesGan & Lee Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A